Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations, capital structure, and governance. This page brings together those SEC filings and pairs them with AI-powered tools to help readers interpret the information more efficiently.
For Amneal, current reports on Form 8-K are a key source of timely disclosures. Recent 8-K filings describe quarterly financial results, including net revenue trends across the Affordable Medicines, Specialty, and AvKARE segments, as well as updates to full-year guidance. Other 8-Ks outline significant financing transactions, such as new seven-year term B loans, senior secured notes due 2032, and amendments to the company’s revolving credit agreement, along with details on collateral, covenants, and maturity profiles.
Filings also cover governance and stockholder matters. For example, Amneal has reported preliminary financial results, changes to board composition when designation rights shifted under a stockholders agreement, and the board’s decision to hold Say-on-Pay advisory votes on an annual basis following stockholder preferences expressed at an annual meeting.
On this page, users can access Amneal’s Forms 8-K and, through links to its broader filing history, locate annual reports on Form 10-K and quarterly reports on Form 10-Q. These longer-form filings typically include segment discussions for Affordable Medicines, Specialty, and AvKARE, risk factor summaries, and explanations of non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS referenced in earnings releases.
AI features on the platform provide summaries and highlights of lengthy filings, helping readers identify key topics such as segment performance, debt structure, covenant changes, and governance decisions without reading every line. Users interested in AMRX can use this page to monitor new filings as they appear on EDGAR, review historical disclosures, and better understand how regulatory documents reflect Amneal’s evolving business and capital structure.
Amneal Pharmaceuticals Executive Vice President Nikita Shah reported multiple equity award vestings and related share withholdings. On March 3, 2026, performance-based restricted stock units granted in 2023 were certified above target, vesting at 200% of the targeted number and settling into an equal number of Class A shares.
Across March 3–4, 2026, Shah acquired Class A Common Stock through exercises and conversions of restricted stock units and performance-based units, while a portion of the resulting shares was automatically disposed of at prices around $13.30 per share to satisfy tax withholding obligations.
Patel Chintu reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Co-CEO Chintu Patel reported equity awards of restricted stock units. On March 2, 2026, he received 190,632 restricted stock units, each representing a contingent right to one share of Class A common stock, vesting in four equal annual installments beginning March 2, 2027.
He was also granted 354,031 performance-based restricted stock units tied to average closing price targets over a three-year performance period. The award can pay out from 0% to 200% of the 354,031 target shares, with any earned units vesting in full on February 28, 2029, representing the maximum number of shares issuable under this grant.
Patel Chirag K. reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals reported that President and Co-CEO Chirag K. Patel received equity awards in the form of restricted stock units. He was granted 190,632 time-based restricted stock units, each representing a right to receive one share of Class A common stock, vesting in four equal annual installments beginning on March 2, 2027.
He also received 354,031 performance-based restricted stock units, tied to the company’s average closing share price over a three-year performance period. The number of shares ultimately delivered may range from 0% to 200% of the target, with any earned units vesting in full on February 28, 2029, and the table reflecting the maximum shares issuable.
Shah Nikita reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Executive Vice President Nikita Shah received equity awards in the form of restricted stock units. She was granted 65,359 time-based restricted stock units and 65,359 performance-based restricted stock units, each representing a right to receive one share of Class A common stock.
The time-based units vest in four equal annual installments starting on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year performance period, with potential payout from 0% to 200% of the target, and any earned units vesting on February 28, 2029.
Amneal Pharmaceuticals Executive Vice President & CFO Tasos Konidaris reported equity awards of restricted stock units. He acquired 72,622 time-based restricted stock units and 72,622 performance-based restricted stock units, each representing a contingent right to receive one share of Amneal’s Class A common stock.
The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based restricted stock units are tied to Amneal’s average closing share price over a three-year performance period and can pay out from 0% to 200% of the 72,622 target shares, with any earned units vesting in full on February 28, 2029.
Daly Jason B. reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals reported that EVP and Chief Legal Officer Jason B. Daly received two equity awards on March 2, 2026. He was granted 65,359 restricted stock units that vest in four equal annual installments beginning March 2, 2027. He also received 65,359 performance-based restricted stock units tied to three-year stock price targets, with any earned units vesting on February 28, 2029.
BOYER ANDREW S reported acquisition or exercise transactions in this Form 4 filing.
Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer reported awards of 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to receive one share of Class A common stock if vesting conditions are met.
The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year period ending February 28, 2029, with payout ranging from 0% to 200% of a 65,359-share target and a maximum of 65,359 shares issuable under the award.
Amneal Pharmaceuticals, Inc. outlines its business and key developments as a diversified global biopharmaceutical company with three segments: Affordable Medicines, Specialty, and AvKARE. Affordable Medicines spans more than 280 generic and biosimilar product families, including injectables, respiratory products, and oncology biosimilars.
The company highlights new collaborations with ApiJect for blow-fill-seal injectables, Metsera (now tied to Pfizer) for weight-loss medicines and Indian manufacturing, and Kashiv for complex injectables and biosimilars. It also licenses IPX203 (CREXONT®) rights to Zambon in Europe and Knight in Canada and Latin America, and markets ONGENTYS® under a BIAL agreement it plans to terminate in 2028.
Recent approvals include U.S. FDA clearance for respiratory generics QVAR® and ProAir® HFA equivalents and denosumab biosimilars Boncresa™ and Oziltus™, bringing its U.S. biosimilar count to five. In Specialty, Amneal launched CREXONT® for Parkinson’s disease and Brekiya® autoinjector for migraine and cluster headache, while RYTARY® faces generic competition.
The filing stresses regulatory, pricing, and reimbursement risks, including U.S. healthcare reform and Medicare negotiation under the Inflation Reduction Act. Customer concentration is significant: four large customers account for about 71% of consolidated net revenue. As of June 30, 2025, aggregate market value of non‑affiliate common stock was approximately $1.7 billion, and as of February 13, 2026, Class A common stock outstanding totaled 314,629,101 shares.
Amneal Pharmaceuticals reported strong fourth quarter and full-year 2025 results, returning solidly to profitability and increasing cash generation. Q4 2025 net revenue rose 11% to $814 million, with GAAP net income of $35 million and diluted EPS of $0.11, while adjusted EBITDA reached $175 million and adjusted diluted EPS was $0.21.
For 2025, net revenue grew to $3.02 billion from $2.79 billion, and net income attributable to Amneal improved to $72 million from a $117 million loss, driven by higher revenue, better gross profit and lower expenses. Adjusted EBITDA increased 10% to $688 million and adjusted diluted EPS rose to $0.83. Specialty revenue grew 19%, Affordable Medicines 4%, and AvKARE 12%.
For 2026, Amneal guides to net revenue of $3.05–$3.15 billion, adjusted EBITDA of $720–$760 million, adjusted diluted EPS of $0.93–$1.03, and operating cash flow of $325–$375 million. Net debt was $2.41 billion at December 31, 2025, implying net leverage of 3.5x, down from 3.9x a year earlier.
Amneal Pharmaceuticals, Inc. amended its term loan credit agreement through a repricing transaction. Existing term loans held by consenting lenders were converted on a cashless basis into new term loans totaling $1,960,076,527.50, and the company added a new term loan of $134,673,472.50 to refinance remaining old loans at par.
The amendment lowers the interest rate margin on the new term loans by 50 basis points to 2.00% for base rate loans and 3.00% for loans based on the secured overnight financing rate, while keeping the August 1, 2032 maturity date unchanged. Amneal estimates approximately $11 million in annualized cash interest savings from this repricing, improving its ongoing financing costs.